Brian Tinmouth
Net worth: 49 349 $ as of 2026-06-29
Net worth: 49 349 $ as of 2026-06-29
Brian Philippe Tinmouth is currently an Independent Director at SCYNEXIS, Inc. since 2019.
Formerly, Mr. Tinmouth was Chief Business & Strategy Officer at Mammoth Biosciences, Inc. from 2022 to 2025, Chief Business & Strategy Officer at Pardes Biosciences, Inc. from 2021 to 2022, Vice President & Head-Business Development at Vertex Pharmaceuticals, Inc. from 2013 to 2020, and Senior Manager at Bain & Co., Inc. from 1997 to 2002.
Mr. Tinmouth completed undergraduate studies at Queen's University and earned an MBA from Harvard Business School.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
SCYNEXIS, INC. 0.12% | 2026-06-25 | 12,125 ( 0.12% ) | 49 349 $ | 2026-06-29 |
| Companies | Position | Start |
|---|---|---|
| SCYNEXIS, INC. | Director/Board Member | 2019-12-12 |
| Companies | Position | End |
|---|---|---|
Mammoth Biosciences, Inc.
Mammoth Biosciences, Inc. Internet Software/ServicesTechnology Services Operates CRISPR-based platform for disease detection | Corporate Officer/Principal | 2025-01-31 |
| PARDES BIOSCIENCES, INC. | Corporate Officer/Principal | 2022-11-29 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 2020-02-29 |
Bain & Co., Inc.
Bain & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Provides strategy, marketing, organization, operations, IT and M&A consulting services | Corporate Officer/Principal | 2001-12-31 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 7 |
|---|---|
Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Bain & Co., Inc.
Bain & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Provides strategy, marketing, organization, operations, IT and M&A consulting services | Commercial Services |
SCYNEXIS, Inc.
SCYNEXIS, Inc. Pharmaceuticals: MajorHealth Technology Develops novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections | Health Technology |
Queen's University
Queen's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mammoth Biosciences, Inc.
Mammoth Biosciences, Inc. Internet Software/ServicesTechnology Services Operates CRISPR-based platform for disease detection | Technology Services |
Pardes Biosciences, Inc.
Pardes Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops oral antiviral treatment for COVID-19 | Health Technology |
Select your edition
All financial news and data tailored to specific country editions